Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes as the Cambridge, Massachusetts-based drug company tries to overcome challenges in selling a new and controversial treatment for Alzheimer's disease, as well as recover from setbacks to its business elsewhere.